Cover Image
市場調查報告書

CytRx Corporation:產品臨床實驗分析

CytRx Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 200940
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
CytRx Corporation:產品臨床實驗分析 CytRx Corporation - Product Pipeline Review - 2015
出版日期: 2015年04月29日 內容資訊: 英文 44 Pages
簡介

CytRx Corporation是專門開發腫瘤生技醫藥的研究開發公司。

本報告針對CytRx Corporation治療藥開發臨床實驗現況與各開發階段比較分析、提供藥劑標的、作用程序、投藥過程、分子種類分類治療藥評價、最新企業新聞發表、後期階段與中止方案相關資料。

CytRx Corporation基本情報

CytRx Corporation概要

  • 主要情報
  • 企業情報

CytRx Corporation:R&D概要

  • 主要治療範圍

CytRx Corporation:臨床實驗回顧

  • 開發階段分類臨床實驗產品
  • 單劑產品
  • 組合產品
    • 組合產品/併用療法模式

CytRx Corporation:臨床實驗產品概況

  • 後期臨床實驗產品
    • 第III期產品/併用療法模式
  • 測試階段臨床實驗產品
    • 第II期產品/併用療法模式
    • 第I期產品/併用療法模式
  • 初期階段臨床實驗產品
    • 前臨床階段產品/併用療法模式

CytRx Corporation:開發階段不明的臨床實驗產品

  • 開發階段不明產品/併用療法模式

CytRx Corporation:藥劑檔案

  • aldoxorubicin
  • bafetinib
  • tamibarotene
  • Cyt-HiPoA
  • Cyt-PLAT
  • Cyt-Topo

CytRx Corporation:臨床實驗分析

  • 標的分類
  • 投藥通路分類
  • 分子種類分類
  • 作用排序分類

CytRx Corporation:最近臨床實驗動向

CytRx Corporation:暫停方案

CytRx Corporation:開發中止的臨床實驗產品

  • 開發中止的臨床實驗產品檔案
    • INNO-305
    • tamibarotene

CytRx Corporation:企業發表

CytRx Corporation:總公司與子公司所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07041CDB

Summary

Global Markets Direct's, 'CytRx Corporation - Product Pipeline Review - 2015', provides an overview of the CytRx Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CytRx Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CytRx Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CytRx Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CytRx Corporation's pipeline products

Reasons to buy

  • Evaluate CytRx Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CytRx Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CytRx Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CytRx Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CytRx Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CytRx Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CytRx Corporation Snapshot
    • CytRx Corporation Overview
    • Key Information
    • Key Facts
  • CytRx Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • CytRx Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • CytRx Corporation - Pipeline Products Glance
    • CytRx Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • CytRx Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • CytRx Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • CytRx Corporation - Drug Profiles
    • aldoxorubicin hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bafetinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cyt-HiPoA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cyt-PLAT
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CytRx Corporation - Pipeline Analysis
    • CytRx Corporation - Pipeline Products by Target
    • CytRx Corporation - Pipeline Products by Route of Administration
    • CytRx Corporation - Pipeline Products by Molecule Type
    • CytRx Corporation - Pipeline Products by Mechanism of Action
  • CytRx Corporation - Recent Pipeline Updates
  • CytRx Corporation - Dormant Projects
  • CytRx Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • INNO-305
      • tamibarotene
  • CytRx Corporation - Company Statement
  • CytRx Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CytRx Corporation, Key Information
  • CytRx Corporation, Key Facts
  • CytRx Corporation - Pipeline by Indication, 2015
  • CytRx Corporation - Pipeline by Stage of Development, 2015
  • CytRx Corporation - Monotherapy Products in Pipeline, 2015
  • CytRx Corporation - Partnered Products in Pipeline, 2015
  • CytRx Corporation - Partnered Products/ Combination Treatment Modalities, 2015
  • CytRx Corporation - Phase III, 2015
  • CytRx Corporation - Phase II, 2015
  • CytRx Corporation - Phase I, 2015
  • CytRx Corporation - Preclinical, 2015
  • CytRx Corporation - Pipeline by Target, 2015
  • CytRx Corporation - Pipeline by Route of Administration, 2015
  • CytRx Corporation - Pipeline by Molecule Type, 2015
  • CytRx Corporation - Pipeline Products by Mechanism of Action, 2015
  • CytRx Corporation - Recent Pipeline Updates, 2015
  • CytRx Corporation - Dormant Developmental Projects,2015
  • CytRx Corporation - Discontinued Pipeline Products, 2015
  • CytRx Corporation, Subsidiaries

List of Figures

  • CytRx Corporation - Pipeline by Top 10 Indication, 2015
  • CytRx Corporation - Pipeline by Stage of Development, 2015
  • CytRx Corporation - Monotherapy Products in Pipeline, 2015
  • CytRx Corporation - Partnered Products in Pipeline, 2015
  • CytRx Corporation - Pipeline by Top 10 Target, 2015
  • CytRx Corporation - Pipeline by Top 10 Route of Administration, 2015
  • CytRx Corporation - Pipeline by Top 10 Molecule Type, 2015
  • CytRx Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top